CRISPR Tx, AZ, and MiNK Tx Report Data in Solid Tumors; AACR 2024 Analysis 1
Here is a brief preview of this blast: AACR 2024 Analysis 1: CRISPR Tx, AZ and MiNK Tx presented clinical and preclinical updates from their programs in solid tumors. Below, Celltelligence provides insights and key context for selected presentations. The following topics are covered: